Silence TherapeuticsNASDAQ: SLN

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.

On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presen.

Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early clinical trial data suggests it can effectively regulate red blood cell production.

Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size is predicted to reach $45 billion by the end of 2036. Full detailed results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, are to be presented at an upcoming medical conference before the end of 2024.

Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration. “This represe.

Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. Positive results achieved in the phase 2 ALPACAR-360 study using zerlasiran for patients with elevated levels of Lp[a] at high risk of ASCVD.

Silence Therapeutics (SLN) experienced a significant increase in its stock price during the last trading session, with above-average trading volume. The recent changes in earnings estimates suggest that there may be additional price growth in the near future.